日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Analytical and clinical validation of PATHWAY Anti-HER-2/neu (4B5) antibody to assess HER2-low status for trastuzumab deruxtecan treatment in breast cancer

PATHWAY 抗 HER-2/neu (4B5) 抗体的分析和临床验证,用于评估乳腺癌患者接受曲妥珠单抗德鲁替康治疗时 HER2 低表达状态

Garrido, Charo; Manoogian, Melissa; Ghambire, Dhiraj; Lucas, Shawn; Karnoub, Maha; Olson, Matthew T; Hicks, David G; Tozbikian, Gary; Prat, Aleix; Ueno, Naoto T; Modi, Shanu; Feng, Wenqin; Pugh, Judith; Hsu, Ching; Tsurutani, Junji; Cameron, David; Harbeck, Nadia; Fang, Qijun; Khambata-Ford, Shirin; Liu, Xuemin; Inge, Landon J; Vitazka, Patrik

Correction: Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms

更正:使用 22C3 抗 PD-L1 抗体在多个自动化免疫组织化学平台上测定 PD-L1 表达

Ilie, Marius; Khambata-Ford, Shirin; Copie-Bergman, Christiane; Huang, Lingkang; Juco, Jonathan; Hofman, Veronique; Hofman, Paul

Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms

使用 22C3 抗 PD-L1 抗体在多种自动化免疫组织化学平台上检测 PD-L1 表达

Ilie, Marius; Khambata-Ford, Shirin; Copie-Bergman, Christiane; Huang, Lingkang; Juco, Jonathan; Hofman, Veronique; Hofman, Paul

Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer

表皮调节素基因表达作为西妥昔单抗治疗晚期结直肠癌疗效的生物标志物

Jonker, D J; Karapetis, C S; Harbison, C; O'Callaghan, C J; Tu, D; Simes, R J; Malone, D P; Langer, C; Tebbutt, N; Price, T J; Shapiro, J; Siu, L L; Wong, R P W; Bjarnason, G; Moore, M J; Zalcberg, J R; Khambata-Ford, S

Identification of promoter regions in the human genome by using a retroviral plasmid library-based functional reporter gene assay

利用基于逆转录病毒质粒文库的功能性报告基因检测方法鉴定人类基因组中的启动子区域

Khambata-Ford, Shirin; Liu, Yueyi; Gleason, Christopher; Dickson, Mark; Altman, Russ B; Batzoglou, Serafim; Myers, Richard M